Published Date: 18 Oct 2024
Low rates of toxicity and salvage cystectomy, with 2-year survival similar to surgery
Read Full News(This Aug 27 story has been republished, with no changes to text.)
Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.
After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.
Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.
Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.
1.
Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma
2.
Research finds COVID-19 mRNA vaccine sparks immune response to fight cancer
3.
A large study found that monolayers were superior in detecting cancer.
4.
Kidney cancer: Understanding what a renal cell carcinoma diagnosis means
5.
When Healthcare Chatbots Fall Short of Human Connection
1.
Emerging Therapies and Technologies Reshaping Oncology: Innovations and Impact in 2025
2.
Drug Safety Surveillance for Advanced Hematology Therapeutic Platforms
3.
Understanding Mean Corpuscular Volume: A Comprehensive Guide
4.
The Revolutionary Treatment of Hodgkin's Lymphoma: A New Hope for the Future
5.
Managing Delayed Toxicities of Targeted Anticancer Therapies
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
2.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation